Nabriva Therapeutics AG (NBRV)
$0.40
$-0.05
(-11.11%)
As on 02-Oct-2023 09:30EDT
Market cap
$5 Mln
Revenue (TTM)
$38 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-23 Mln
-
ROE
-2.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.1
-
Debt to Equity
0.1
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
3,201,460
10 Years Aggregate
CFO
$-468.35 Mln
EBITDA
$-486.42 Mln
Net Profit
$-535.09 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nabriva Therapeutics AG (NBRV)
| -78.8 | -38.0 | -73.5 | -80.8 | -85.5 | -77.5 | -- |
|
BSE Sensex*
| -11.8 | -4.8 | 1.1 | -7.9 | 3.9 | 5.1 | 10.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Nabriva Therapeutics AG (NBRV)
| -87.4 | -75.2 | -81.7 | -9.6 | -75.4 | 0.3 | -38.0 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Nabriva Therapeutics AG (NBRV)
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the... treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. Read more
-
CEO & Director
Mr. Theodore R. Schroeder
-
CEO & Director
Mr. Theodore R. Schroeder
-
Headquarters
Dublin
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Nabriva Therapeutics AG (NBRV)
What is the current share price of Nabriva Therapeutics AG (NBRV) Today?
The share price of Nabriva Therapeutics AG (NBRV) is $0.40 (NASDAQ) as of 02-Oct-2023 09:30 EDT. Nabriva Therapeutics AG (NBRV) has given a return of -85.55% in the last 3 years.
What is the current PB & PE ratio of Nabriva Therapeutics AG (NBRV)?
Since, TTM earnings of Nabriva Therapeutics AG (NBRV) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
2018 |
-- |
-- |
What is the 52 Week High and Low of Nabriva Therapeutics AG (NBRV)?
The 52-week high and low of Nabriva Therapeutics AG (NBRV) are Rs -- and Rs -- as of 10-Sep-2026.
What is the market cap of Nabriva Therapeutics AG (NBRV)?
Nabriva Therapeutics AG (NBRV) has a market capitalisation of $ 5 Mln as on 02-Oct-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Nabriva Therapeutics AG (NBRV)?
Before investing in Nabriva Therapeutics AG (NBRV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.